NCT02829775 / 2004-002093-30: A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies |
|
|
| Completed | 2/3 | 9 | Canada, Europe, RoW | Pegylated Interferon Alfa-2a, Pegasys, Recombinant Interferon Alfa 2a, Roferon-A | Hoffmann-La Roche | Chronic Myelogenous Leukemia, Malignant Melanoma, Renal Cell Carcinoma | 01/08 | 01/08 | | |
